ATE318599T1 - Famotidin-injektionen - Google Patents

Famotidin-injektionen

Info

Publication number
ATE318599T1
ATE318599T1 AT01272263T AT01272263T ATE318599T1 AT E318599 T1 ATE318599 T1 AT E318599T1 AT 01272263 T AT01272263 T AT 01272263T AT 01272263 T AT01272263 T AT 01272263T AT E318599 T1 ATE318599 T1 AT E318599T1
Authority
AT
Austria
Prior art keywords
famotidine
injections
impairing
absorption
far
Prior art date
Application number
AT01272263T
Other languages
English (en)
Inventor
Katsunori Nakata
Hiroshi Yatabe
Tsukasa Nishikawahara
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE318599T1 publication Critical patent/ATE318599T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Fishing Rods (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
AT01272263T 2000-12-22 2001-12-20 Famotidin-injektionen ATE318599T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000389887 2000-12-22

Publications (1)

Publication Number Publication Date
ATE318599T1 true ATE318599T1 (de) 2006-03-15

Family

ID=18856345

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01272263T ATE318599T1 (de) 2000-12-22 2001-12-20 Famotidin-injektionen

Country Status (12)

Country Link
US (1) US7094414B2 (de)
EP (1) EP1352654B1 (de)
JP (1) JP3648531B2 (de)
KR (1) KR100848794B1 (de)
CN (1) CN100438871C (de)
AT (1) ATE318599T1 (de)
CA (1) CA2432037C (de)
DE (1) DE60117467T2 (de)
DK (1) DK1352654T3 (de)
ES (1) ES2259313T3 (de)
PT (1) PT1352654E (de)
WO (1) WO2002051411A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185119A1 (en) * 2003-02-26 2004-09-23 Theuer Richard C. Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency
CN101631593B (zh) * 2007-03-12 2014-08-13 帝斯曼知识产权资产管理有限公司 化妆品组合物
US8058296B2 (en) * 2008-11-25 2011-11-15 Richard Tokunaga Treatment and prevention of deleterious effects associated with alcohol consumption
NZ599082A (en) * 2009-09-04 2014-06-27 Munisekhar Medasani Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same
CN101972248B (zh) * 2010-10-09 2012-02-01 江苏奥赛康药业股份有限公司 一种供注射用的法莫替丁组合物及其制备方法
CN103446048A (zh) * 2013-09-12 2013-12-18 南京正宽医药科技有限公司 一种法莫替丁注射液及其制备方法
CN103877579B (zh) * 2014-03-24 2015-08-26 海南双成药业股份有限公司 一种含有法莫替丁的药物组合物及其制剂
WO2017091166A1 (en) 2015-11-26 2017-06-01 Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. Stable pharmaceutical compositions and process for their preparation
JP7090845B2 (ja) * 2018-08-03 2022-06-27 高田製薬株式会社 パロノセトロン含有液体組成物
CN111904936B (zh) * 2020-08-28 2022-07-19 开封康诺药业有限公司 一种法莫替丁冻干粉针剂
CN113197869A (zh) * 2021-04-13 2021-08-03 河北智同生物制药股份有限公司 一种注射用法莫替丁冻干粉针剂及制备方法
CN116898796A (zh) * 2022-04-20 2023-10-20 广州远跖恒创医药科技有限公司 一种法莫替丁注射液的制备方法
WO2024062287A1 (en) * 2022-09-21 2024-03-28 Maiva Pharma Private Limited A premixed room temperature stable composition of famotidine for intravenous bolus injection and method thereof
CN115737548B (zh) * 2022-11-21 2024-12-27 四川汇宇制药股份有限公司 一种法莫替丁注射液的制备方法
CN115957182A (zh) * 2022-12-27 2023-04-14 成都康泰源医药科技有限责任公司 一种法莫替丁注射液及其制备方法
CN116059163A (zh) * 2023-02-13 2023-05-05 河北智恒医药科技股份有限公司 一种法莫替丁注射液的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4612756B1 (de) 1969-09-22 1971-04-01
JPS58103312A (ja) 1981-12-15 1983-06-20 Yamanouchi Pharmaceut Co Ltd 難溶性医薬品の注射剤用水溶液
US4684630A (en) * 1983-08-24 1987-08-04 Repta Arnold J Method of parenterally delivering drugs and related compositions
TW280770B (de) * 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
US5650421A (en) * 1995-03-31 1997-07-22 Baxter International Inc. Premixed famotidine formulation
JP3213283B2 (ja) * 1997-10-16 2001-10-02 山之内製薬株式会社 注射剤
AU718356B2 (en) 1998-01-12 2000-04-13 Panacea Biotec Limited A parenteral water-miscible non-intensely coloured injectable composition of non-steroidal anit-inflammatory drugs
CO4810371A1 (es) * 1998-02-10 1999-06-30 Gensia Sicor Inc Composicion de propofol que contiene sulfito

Also Published As

Publication number Publication date
WO2002051411A1 (fr) 2002-07-04
KR100848794B1 (ko) 2008-07-28
CN100438871C (zh) 2008-12-03
US7094414B2 (en) 2006-08-22
DE60117467T2 (de) 2006-09-28
DK1352654T3 (da) 2006-07-03
KR20030063457A (ko) 2003-07-28
US20040067993A1 (en) 2004-04-08
CA2432037C (en) 2008-08-12
EP1352654B1 (de) 2006-03-01
ES2259313T3 (es) 2006-10-01
JPWO2002051411A1 (ja) 2004-04-22
EP1352654A4 (de) 2005-01-19
JP3648531B2 (ja) 2005-05-18
CA2432037A1 (en) 2002-07-04
DE60117467D1 (de) 2006-04-27
PT1352654E (pt) 2006-06-30
EP1352654A1 (de) 2003-10-15
CN1482910A (zh) 2004-03-17

Similar Documents

Publication Publication Date Title
DK1352654T3 (da) Famotidininjektioner
DK0431663T3 (da) Stabiliserende opløsninger af psykotrope midler
PT1349856E (pt) Compostos de isoindolina-1-ona activadores da glicocinase
PT1086706E (pt) Composicao estabilizada que compreende um medicamento nootropico
NO20042172L (no) Insulinmolekyl med forlenget virkningstid
ATE357232T1 (de) Hochkonzentrierte stabile meloxicamlösungen zur nadellosen injektion
DE60117605D1 (de) Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
ECSP014062A (es) Activadores de fenilamida glucoquinasa para-amina sustituida
EA200200431A1 (ru) Фармацевтические композиции, обеспечивающие повышенные концентрации лекарства
BR0317696A (pt) Composição para branqueamento
PT1282611E (pt) Fenilacetamidas substituidas e sua utilizacao como activadores da glucocinase
ID26033A (id) Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
DE60329237D1 (de) Kristalline form von linezolid
DE60114865D1 (de) Heterologe herstellung von polyketiden
EA200200790A1 (ru) Аминированные производные дигидро-1,3,5-триазина и их применение в терапии
ATE382369T1 (de) Gebrauchsfertige paracetamol injektionslösungen enthaltend propylenglykol als einziges cosolvens
ATE512208T1 (de) Duftstoffkombination enthaltend 3, 7-dymethyl-6- en-nitril (citronellyl nitril) als geranonitril- substitut
DE60104687D1 (de) Mikrofiltration unter verwendung von aktivkohle
DE60117938D1 (de) Vorspannen von Bauteilen
ATE335068T1 (de) Bleichmittelzusammensetzung enthaltende alkoxyliertenbenzoesäure
DE50112381D1 (de) Pflaster
DE60124516D1 (de) Kombination des lezithins mit ascorbinsäure
EA200300917A1 (ru) Порошковый состав
DE60221522D1 (de) Minoxidil-enthaltende flüssige zusammensetzung
ES2190921T3 (es) 4-alcanoil-3-tiazolinas y su empleo como perfumes y aromas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1352654

Country of ref document: EP